Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from BioHarvest Sciences ( (BHST) ).
BioHarvest Sciences reported that 2025 was its first full year as a NASDAQ-listed company, entering 2026 with an annualized revenue run rate above US$36 million, gross margins over 60%, and a significantly strengthened balance sheet aimed at supporting continued growth and a near-term move to adjusted EBITDA breakeven. The VINIA-branded D2C portfolio expanded with new formats such as capsules, hot beverages, blood flow hydration and daily chews, pushing active users beyond 85,000 and maintaining a subscription-heavy customer base and leading category position on Amazon, while the newly launched Blood Flow Hydration product is being positioned to capture share in the US$13 billion U.S. electrolyte hydration market. In parallel, the CDMO services division reached an inflection point by securing anchor partnerships across multiple industries, onboarding two major new plant-based compounds in premium fragrance and saffron-based nutraceuticals, and building AI-enabled discovery and tissue-culture capabilities, with management signaling that CDMO revenues are expected to eventually surpass the products division as the platform scales and the pipeline of potential customers continues to mature.
The most recent analyst rating on (BHST) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on BioHarvest Sciences stock, see the BHST Stock Forecast page.
Spark’s Take on BHST Stock
According to Spark, TipRanks’ AI Analyst, BHST is a Neutral.
The score is held down primarily by weak financial performance (ongoing net losses, negative operating/free cash flow, and elevated leverage) and bearish technicals (below key moving averages with negative MACD). The latest earnings call adds support via strong revenue growth, improving gross margins, and guidance pointing toward adjusted EBITDA breakeven, but valuation remains constrained by unprofitability and no dividend.
To see Spark’s full report on BHST stock, click here.
More about BioHarvest Sciences
BioHarvest Sciences Inc. is a biotechnology company pioneering a patented Botanical Synthesis technology used to produce plant-derived compounds for use in consumer health products and contract development and manufacturing (CDMO) services. The company operates two complementary business units: a direct-to-consumer (D2C) products division anchored by its VINIA® brand targeting longevity, vitality, cognitive health and overall wellness, and a CDMO services arm that develops high-value botanical ingredients for pharmaceutical, nutrition, fragrance and nutraceutical markets, with a growing presence in the U.S. and international segments.
Average Trading Volume: 80,986
Technical Sentiment Signal: Buy
Current Market Cap: $122.6M
See more data about BHST stock on TipRanks’ Stock Analysis page.